EUGENE BUTCHER, M.D.
Medical Practice at Corte Madera Rd, Menlo Park, CA
License number
California G45577
Category
Medical Practice
Type
Anatomic Pathology
Address
Address
230 Corte Madera Rd, Menlo Park, CA 94028
Phone
(650) 759-3307
Personal information
See more information about EUGENE BUTCHER at radaris.comName
Address
Phone
2700 Twining Rd, Ukiah, CA 95482
230 Corte Madera Rd, Portola Vally, CA 94028
2700 Twining Rd, Ukiah, CA 95482
230 Corte Madera Rd, Portola Valley, CA 94028
10624 Yosemite Blvd, Waterford, CA 95386
Professional information
Anti-Leukocyte Recruitment Therapy For The Treatment Of Seizures And Epilepsy
US Patent:
8383116, Feb 26, 2013
Filed:
Oct 13, 2009
Appl. No.:
12/587879
Inventors:
Paolo Francesco Fabene - Iocalita' Santa Lucia ai Monti, IT
Eugene C. Butcher - Portola Valley CA, US
Gabriela Constantin - San Floriano, IT
Eugene C. Butcher - Portola Valley CA, US
Gabriela Constantin - San Floriano, IT
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
A61K 39/395, A61K 49/00, C07K 16/00
US Classification:
4241391, 424 91, 5303871
Abstract:
Methods are provided for the prevention and treatment of seizures and epilepsy. It is shown herein that leukocyte recruitment plays a key role in the pathogenesis of epilepsy. Treatment with an agent that inhibits leukocyte recruitment has therapeutic and preventative effects in blocking recurrent seizures and epilepsy.
Method For Identifying Agents Which Modulate Chemokine ÂMecâ-Induced Functions Of Ccr3
US Patent:
6692922, Feb 17, 2004
Filed:
Aug 15, 2001
Appl. No.:
09/931381
Inventors:
Eugene C. Butcher - Portola Valley CA
Eric J. Kunkel - Redwood City CA
Junliang Pan - El Cerrito CA
Eric J. Kunkel - Redwood City CA
Junliang Pan - El Cerrito CA
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
Millennium Pharmaceuticals, Inc. - Cambridge MA
Millennium Pharmaceuticals, Inc. - Cambridge MA
International Classification:
G01N 3353
US Classification:
435 71, 530350
Abstract:
The invention relates to the interaction of MEC with CCR3 and/or CCR10 and to agents (e. g. , ligands, antibodies, antagonists, agonists, inhibitors, promoters) which alter said interaction. In one aspect, the invention relates to methods for detecting or identifying an agent (i. e. , molecule or compound) which can modulate (inhibit, promote) the binding of MEC to CCR3 and/or CCR10. In another aspect, the invention relates to a method of treating a subject having an inflammatory condition, comprising administering to the subject an effective amount of an agent which modulates the binding of MEC to CCR3 and/or CCR10.
Methods And Compositions For The Inhibition Of Cancer Metastasis Mediated By Endothelial Adhesion Molecules
US Patent:
6465434, Oct 15, 2002
Filed:
Nov 23, 1999
Appl. No.:
09/447532
Inventors:
John L. Magnani - Frederick MD 21702
Eugene C. Butcher - Portola Valley CA
Ellen L. Berg - Palo Alto CA
Eugene C. Butcher - Portola Valley CA
Ellen L. Berg - Palo Alto CA
Assignee:
Stanford University - Palo Alto CA
John L. Magnani - Rockville MD
John L. Magnani - Rockville MD
International Classification:
A01N 4304
US Classification:
514 23, 514 53, 514 54, 514 61
Abstract:
Methods and compositions are disclosed for the inhibition of cancer metastases mediated by endothelial adhesion molecules. The present invention discloses that sialyl Le and di-sialyl Le , which are expressed at the surface of cancer cells, function as a binding partner for LEC-CAMs, such as ELAM-1, which are expressed at the surface of endothelial cells. The present invention also discloses that LEC-CAMs, such as ELAM-1, involved in cancer metastasis share a carbohydrate domain common to both sialyl Le and sialyl Le. Antibodies, saccharides, glycoconjugates, enzyme inhibitors and other compounds may be used in the methods of the present invention to inhibit the binding of malignant cells to endothelial cells for a variety of purposes in vivo and in vitro.
Leukocyte Homing Modulation
US Patent:
6387884, May 14, 2002
Filed:
Nov 9, 1994
Appl. No.:
08/336417
Inventors:
John L. Magnani - Gaithersburg MD 20879
Eugene C. Butcher - Portola Valley CA
Ellen L. Berg - Fremont CA
Eugene C. Butcher - Portola Valley CA
Ellen L. Berg - Fremont CA
Assignee:
Stanford University - Palo Alto CA
John L. Magnani - Rockville MD
John L. Magnani - Rockville MD
International Classification:
A61K 3170
US Classification:
514 25, 514 8, 514 23, 514 53, 514 54, 514 61, 514 62, 530395, 536 111, 536 41, 536 172, 536 187
Abstract:
Novel methods and compositions are provided for modulating homing of leukocytes, particularly lymphocytes, where the compounds are cross-reactive with Neu5Ac2-3Gal1-X[Fuc1-y]GlcNAc, where one of x and y is three and the other is four. These compounds may be administered to a host associated with inflammation, to avoid the deleterious effects of leukocyte infiltration.
Methods For The Inhibition Of Cancer Metastasis Mediated By Endothelial Adhesion Molecules
US Patent:
6121233, Sep 19, 2000
Filed:
May 5, 1994
Appl. No.:
8/238684
Inventors:
John L. Magnani - Rockville MD
Eugene C. Butcher - Portola Valley CA
Ellen L. Berg - Fremont CA
Eugene C. Butcher - Portola Valley CA
Ellen L. Berg - Fremont CA
International Classification:
A61K 31715
US Classification:
514 8
Abstract:
Methods and compositions are disclosed for the inhibition of cancer metastases mediated by endothelial adhesion molecules. The present invention discloses that sialyl Le. sup. a and di-sialyl Le. sup. a, which are expressed at the surface of cancer cells, function as a binding partner for LEC-CAMs, such as ELAM-1, which are expressed at the surface of endothelial cells. The present invention also discloses that LEC-CAMs, such as ELAM-1, involved in cancer metastasis share a carbohydrate domain common to both sialyl Le. sup. a and sialyl Le. sup. x. Antibodies, saccharides, glycoconjugates, enzyme inhibitors and other compounds may be used in the methods of the present invention to inhibit the binding of malignant cells to endothelial cells for a variety of purposes in vivo and in vitro.
Modulation Of Systemic Memory T Cell Trafficking
US Patent:
6245332, Jun 12, 2001
Filed:
Jan 15, 1999
Appl. No.:
9/232878
Inventors:
Eugene C. Butcher - Portola Valley CA
James J. Campbell - Palo Alto CA
Lijun Wu - Reading MA
James B. Rottman - Sudbury MA
James J. Campbell - Palo Alto CA
Lijun Wu - Reading MA
James B. Rottman - Sudbury MA
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
LeukoSite, Inc. - Cambridge MA
LeukoSite, Inc. - Cambridge MA
International Classification:
A61K 3938, A61K 39395, A61K 3800, A61K 4500, G01N 3353
US Classification:
4241841
Abstract:
Methods are provided to specifically modulate the trafficking of systemic memory T cells, particularly CD4+ T cells, without affecting naive T cells or intestinal memory T cells. It is shown that systemic memory T cells, which are characterized as CD45Ra. sup. -, and integrin. alpha. 4. beta. 7. sup. -, express high levels of CCR4. Ligands of CCR4, such as TARC or MDC, act as an adhesion trigger, wherein upon CCR4 binding, these cells undergo integrin-dependent arrest to the appropriate vascular receptor(s). This arrest acts to localize the cells at the target site. The methods of the invention manipulate this triggering, and CCR4 mediated chemotaxis, to affect the localization of T cells in targeted tissues. In one embodiment of the invention, the active agent is a CCR4 agonist, that acts to enhance T cell localization. In an alternative embodiment, the agent is an antagonist that blocks CCR4 biological activity.
Function Homology Screening
US Patent:
2008006, Mar 13, 2008
Filed:
Oct 30, 2007
Appl. No.:
11/929841
Inventors:
Ellen Berg - Palo Alto CA, US
Eugene Butcher - Portola Valley CA, US
Jennifer Melrose - La Honda CA, US
Eugene Butcher - Portola Valley CA, US
Jennifer Melrose - La Honda CA, US
International Classification:
C12Q 1/02
US Classification:
435029000
Abstract:
A method of screening biologically active agent based on the analysis of complex biological responses in culture. Methods for selecting cells and culture conditions for such screens are provided, as well as the identification of an optimized set of discrete parameters to be measured, and the use of biomap analysis for rapid identification and characterization of drug candidates, genetic sequences acting pathways, and the like. A feature of the invention is simultaneous screening of a large number of cellular pathways, and the rapid identification of compounds that cause cellular responses.
Target For Regulating Multiple Sclerosis
US Patent:
8038992, Oct 18, 2011
Filed:
May 11, 2009
Appl. No.:
12/463840
Inventors:
Kareem Graham - Mountain View CA, US
Brian A. Zabel - Mountain View CA, US
Eugene C. Butcher - Portola Valley CA, US
Brian A. Zabel - Mountain View CA, US
Eugene C. Butcher - Portola Valley CA, US
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
Department of Veterans Affairs - Washington DC
Department of Veterans Affairs - Washington DC
International Classification:
A61K 39/395
US Classification:
4241301, 4241331, 4241431, 4241441
Abstract:
Methods are provided for decreasing demyelinating inflammatory disease in a subject by inhibiting the activity of chemokine-like receptor 1 (CMKLR1). Methods are also provided for screening for agents that find use in treating demyelinating inflammatory disease in a subject.
Function Homology Screening
US Patent:
2008007, Mar 20, 2008
Filed:
Oct 30, 2007
Appl. No.:
11/929790
Inventors:
Ellen Berg - Palo Alto CA, US
Eugene Butcher - Portola Valley CA, US
Jennifer Melrose - Burlingame CA, US
Ivan Plavec - Sunnyvale CA, US
Eugene Butcher - Portola Valley CA, US
Jennifer Melrose - Burlingame CA, US
Ivan Plavec - Sunnyvale CA, US
International Classification:
C12Q 1/02
US Classification:
435029000
Abstract:
A method of screening biologically active agent based on the analysis of complex biological responses in culture. Methods for selecting cells and culture conditions for such screens are provided, as well as the identification of an optimized set of discrete parameters to be measured, and the use of biomap analysis for rapid identification and characterization of drug candidates, genetic sequences acting pathways, and the like. A feature of the invention is simultaneous screening of a large number of cellular pathways, and the rapid identification of compounds that cause cellular responses.
Tolerogenic Populations Of Dendritic Cells
US Patent:
2010008, Apr 1, 2010
Filed:
Sep 24, 2009
Appl. No.:
12/566454
Inventors:
Husein Hadeiba - Palo Alto CA, US
Eugene C. Butcher - Portola Valley CA, US
Eugene C. Butcher - Portola Valley CA, US
International Classification:
A61K 39/00, C12N 5/071, A61P 37/02
US Classification:
4241841, 435325, 435355, 435372
Abstract:
Tolerogenic populations of dendritic cells are provided, where the dendritic cells are characterized by expression of select tissue-specific homing receptors including the chemokine receptors CCR9; or CMKLR1; or the integrin CD103. The dendritic cells may be conventional/myeloid or plasmacytoid dendritic cells. The cells may be isolated from lymphoid tissue, from blood, or from in vitro culture, e.g. bone marrow culture, etc. Methods are provided for their identification, isolation and targeting in immunotherapeutic interventions in suppressing inflammatory disorders including autoimmunity, transplantation responses and allergic diseases. In some embodiments dendritic cell populations are fixed to render them immunosuppressive, thus allowing the cells to be typed and banked for future use.